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Sample introduction interface for on-chip nucleic
acid-based analysis of Helicobacter pylori from
stool samples†
O. Mosley,a L. Melling,a M. D. Tarn,b C. Kemp,b M. M. N. Esfahani,c N. Pamme*b
and K. J. Shaw*a
Despite recent advances in microfluidic-based integrated diagnostic systems, the sample introduction
interface, especially with regards to large volume samples, has often been neglected. We present a sample
introduction interface that allows direct on-chip processing of crude stool samples for the detection of
Helicobacter pylori (H. pylori). The principle of IFAST (immiscible filtration assisted by surface tension) was
adapted to include a large volume sample chamber with a septum-based interface for stool sample intro-
duction. Solid chaotropic salt and dry superparamagnetic particles (PMPs) could be stored on-chip and
reconstituted upon sample addition, simplifying the process of release of DNA from H. pylori cells and its
binding to the PMPs. Finally, the PMPs were pulled via a magnet through a washing chamber containing an
immiscible oil solution and into an elution chamber where the DNA was released into aqueous media for
subsequent analysis. The entire process required only 7 min while enabling a 40-fold reduction in working
volume from crude biological samples. The combination of a real-world interface and rapid DNA extraction
offers the potential for the methodology to be used in point-of-care (POC) devices.
Introduction
It is estimated that approximately two-thirds of the world's
population harbours Helicobacter pylori (H. pylori), a Gram-
negative microorganism that colonises the gastric mucosa in
the human stomach.1 H. pylori has been shown to have a sig-
nificant role in the pathogenesis of chronic gastritis, peptic
ulcers and more importantly gastric cancer.2 Different strains
have varying abilities to cause inflammatory changes but the
phenotype of H. pylori that expresses cytotoxin-associated pro-
tein (CagA) causes a higher degree of acute inflammation and
is three times more likely to lead to gastric carcinogenesis.3 A
wide variety of methods are available to detect H. pylori in-
cluding immunochromatogenic assays, histology and culture.
However, only polymerase chain reaction (PCR)-based assays
have the ability to identify particular strains including those
which are CagA+.4 Such methods which incorporate
genotyping are therefore advantageous in identifying patients
who are at higher risk of complications resulting from H. py-
lori infection.5
Rapid and efficient diagnosis is thus important in eradi-
cating the infection and reducing the risk of gastric cancer
development. To this end, microfluidic and lab-on-a-chip
(LOC) devices offer considerable advantages for use in point-
of-care (POC) diagnostics6,7 due to increased analysis speed
and sensitivity, reduced reagent usage and the possibility for
full automation. Despite this great potential, the development
of real-world sample introduction interfaces remains chal-
lenging. Currently, the majority of published integrated de-
vices either use simulated samples or require excessive off-
chip or on-chip sample pre-treatment to achieve the desired
specimen volume reduction and target concentrations. Simu-
lated samples include the use of a few microlitres of highly con-
centrated bacterial cell cultures8 or high virus titre matrices9
that rarely represent target concentrations and purities found
in clinical samples. Low target concentrations, such as those
present in urine and stool samples, therefore require the use
of larger sample volumes to assure sensitivity of the assay. In
particular, the analysis of stool samples results in the need
for considerable off-chip sample pre-treatment, such as cen-
trifugation and filtration steps10 and chemical lysis11 prior to
addition to a microfluidic device, all of which can be some-
what time-consuming. Furthermore, research in this area has
focussed on the detection of infectious agents, such as
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Clostridium difficile, which cause diarrhoea resulting in liquid
stool samples that are easier to introduce into microfluidic
systems for analysis.10,12,13 Thus, the development of a real-
world interface for the direct manipulation of crude biologi-
cal samples has largely been ignored, and represents a bar-
rier between the research and clinical environments.
Superparamagnetic particles (PMPs) have become very
popular as solid supports for nucleic acid purification in the
detection of infectious diseases.14 With a suitable surface
functionality, such as silica or chitosan, the particles will cap-
ture DNA in a sample and their magnetic properties allow
them to be held in place by an external magnet while the
sample is removed and washing steps are applied. However,
these methods typically require a great deal of time and man-
ual handling. As a consequence, magnetic particle-based pro-
cedures have been incorporated into microfluidic devices
with great success,15–17 thanks to the reduction in diffusion
distances, procedural times, and the ease of particle manipu-
lation. Magnetic particle-based procedures integrated with
microfluidic devices have proven particularly effective for the
purification of nucleic acids prior to their amplification and
analysis,18 but many techniques involve complex chip setups19,20
and laborious multi-step procedures involving the trapping of
magnetic particles while solutions are pumped over them.20
A simple method of achieving DNA or RNA extraction
involves the introduction of PMPs into a contained sample
volume, before moving the particles via a magnet through
multiple washing solutions, leaving behind any unwanted
and unbound material. Early examples of this mechanism
employed the use of droplets on open, superhydrophobic
microfluidic platforms, in which magnetic particles would be
moved between stationary sample and washing droplets sepa-
rated via an immiscible phase such as oil21–24 or air.25–27
However, these techniques often require either mechani-
cal25,26 or electromagnetic21,23,24 actuation, adding complexity
to the system in terms of both fabrication and operation.
A recent development from the group of Beebe is that of
immiscible filtration assisted by surface tension (IFAST), in
which rather than having solutions contained in droplets
they are instead added to interconnected microwells sepa-
rated by small “gated” regions.28 The chambers are filled
with alternating aqueous and oil phases to form “virtual
walls” between each chamber, controlled by the surface ten-
sion, but allowing magnetic particles to be pulled through
these walls and thus through each chamber in one smooth
yet fast motion via a handheld magnet. This allows simple
and rapid DNA extraction to be performed with minimal
setup and materials, and by the “unskilled” end-user. The
standard IFAST design features three chambers consisting of
(i) aqueous sample solution to which PMPs are added, (ii) an
immiscible oil phase for washing of particles, and (iii) elution
buffer that can be collected for off-chip nucleic acid amplifi-
cation and analysis. So far this method has been applied
to the purification of RNA28–31 and DNA,31,32 as well as for
cell isolation33–35 and immunoassays.36 Further develop-
ments have included automation of the devices,37,38 their
fabrication from wax,30,38 and variants such as vertical IFAST
(VerIFAST),34,35 and SNARE (selective nucleic acid removal via
exclusion).31 Similar techniques have also been developed by
other research groups, in which different immiscible phases
have been employed including liquid wax,39 paraffin wax,40
and air.41–44 Furthermore, miscible phases have recently been
employed for particle washing by using phaseguides to pat-
tern interfaces between adjacent aqueous solutions.45,46
Here, we have exploited and considerably modified the
IFAST principle to develop a sample introduction interface
that enables direct processing of stool samples. Stool sam-
ples are particularly challenging for diagnostic analysis
through molecular biology techniques as they exhibit high
variability in terms of consistency of samples, the presence
of PCR inhibitors and low target analyte concentrations,
hence the requirement of the sample pre-treatment and pre-
concentration steps described earlier. IFAST is usually con-
ducted in chambers of 10 μL volumes, while in our high vol-
ume IFAST system the issue of low biomarker concentration
is negated by the use of a large sample chamber, while the
IFAST process itself allows rapid DNA purification, concen-
tration, and elution, in a single device (Fig. 1). Initial experi-
ments were performed using E. coli as a model Gram-
negative pathogenic target before moving onto analysis of
H. pylori (also Gram-negative) from clinical stool samples.
The novelty of the reported approach lies in (1) the design
of the sample chamber which enables a 40-fold reduction in
working volume, (2) the choice of detergent-free solid cell
lysis and DNA binding agent that is reconstituted by the
sample itself, (3) a unique PDMS/optical adhesive bonding
approach which facilitated the formation of a stable but
immiscible barrier, and (4) the real-world interface created
using a septum-based sample introduction design.
Experimental
Chemicals, apparatus and samples
All aqueous solutions were prepared in filtered, purified wa-
ter (18.2 MΩ cm at 25 °C). For IFAST devices, a Sylgard® 184
Silicone Elastomer Kit was purchased from Dow Corning, op-
tical adhesive film (100 μm thickness, Adhesive PCR Film
Seal) from Thermo Scientific, UK, and microscope cover slips
(24 × 24 × 0.017 mm3) from Scientific Laboratory Supplies,
UK. Guanidine hydrochloride (GuHCl) and MagneSil para-
magnetic particles (2–14 μm diameter, ∼27 m2 g−1 surface
area) were purchased from Promega, UK.47 Biomix™ for DNA
amplification and the DNA size ladder, Hyperladder™ V,
were obtained from Bioline Reagents Ltd, UK. Primers for UreC
(H. pylori specific, forward: 5′ AAGCTTTTAGGGGTGTTAGGGGTTT
3′, reverse: 5′ AAGCTTACTTTCTAACACTAACGC 3′) and CagA
(CagA strain specific, forward: 5′ AATACACCAACGCCTCCAAG
3′, reverse: 5′ TTGTTGCCGCTTTTGCTCTC 3′) were custom-
made by Life Technologies, UK.48 Agarose and loading dye for
electrophoresis were purchased from Sigma-Aldrich, UK. DNA
quantification was performed on a Multiskan™ GO Micro-
plate Spectrophotometer (Thermo Scientific, UK). DNA
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amplification was carried out using a Q-cycler 96 thermal cy-
cler (Hain Lifesciences Ltd, UK). Escherichia coli (E. coli) cells
(NCTC 9001) were obtained from the National Collection of
Type Cultures, UK. Clinical stool samples were obtained from
NHS Chesterfield Laboratories; samples were fully anonymised
and were selected on the basis that they had previously been
tested for H. pylori during routine clinical testing using a
Proflow™ H. pylori test (ProLab, UK).
Chip fabrication and setup
The integrated device consisted of either three (Fig. 2) or five
(Fig. 3) chambers arranged in a linear configuration: a single
sample chamber (26 × 26 × 4 mm3 [length × width × height]),
and washing and elution chambers (each 3 × 3 × 4 mm3). These
were interconnected by gated regions consisting of trapezoi-
dal microfluidic conduits that narrowed from 3 mm to 500 μm
in width, with a height of 500 μm. The devices themselves
were fabricated in a novel manner. A mould was designed in
SolidWorks 2011 (Dassault Systèmes SolidWorks Corp.,
France) and fabricated out of aluminium on a CNC milling
machine (M7, Datron AG, Germany). Due to limitations in
spatial resolution with the CNC machine and available tools,
the mould was prepared featuring the final channel design.
This was then used to fabricate a negative relief of the design
in polyĲmethyl methacrylate) (PMMA) using an injection
moulding machine (Babyplast 6/10P, Rambaldi+Co, Italy).
The final device was prepared by pouring PDMS (consisting
of a mixture of prepolymer and curing agent in a 10 : 1 ratio
and degassed for 1 h) onto the PMMA mould and curing at
80 °C for 30 min, before peeling the PDMS substrate off. The
process is shown in more detail in the ESI† (see Fig. S-1). The
device was sealed with a double layer of optical adhesive film
underneath the PDMS substrate to provide support and a
microscope cover slip was adhered to the bottom of the sam-
ple chamber to overcome initial sample loading difficulties
caused by the hydrophobic properties of the optical adhesive
film. A single layer of optical adhesive film, featuring holes to
allow access to the wash and elution chambers, was used to
seal the top of the device.
A real-world interface was constructed for sample intro-
duction via the holes in the optical film lid above the sample
Fig. 1 Schematic of the DNA extraction process, showing (a) sample loading and cell lysis, (b) mixing of PMPs with the sample for DNA binding, (c)
transfer of PMPs through the immiscible phase for washing, and (d) elution of DNA from the PMPs followed by collection for off-chip analysis. The
design was later amended to include two extra downstream chambers for additional washing (see Fig. 3 for further details). Schematics are not to scale.
Fig. 2 (a) Schematic of the 3-chamber DNA purification device. (b)
Photograph of the PDMS chip filled with inks and oil. (c) Exploded
schematic of the final setup, showing: (i) filter, (ii) vent, (iii) septum, (iv)
septum seat, (v) sample chamber containing a glass microscope slide
on the base, (vi) immiscible phase chamber, (vii) elution chamber, (viii)
optical adhesive film lid, (ix) PDMS layer, and (x) optical adhesive film
bottom layer. (d) Photograph of a fully assembled device.
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chamber, consisting of a septum for sample introduction and
an air vent (Fig. 2c and d). The septum was prepared by cut-
ting a standard capillary gel electrophoresis septum to size
and seating it in the top of a cut-to-size pipette tip (100 μL)
that was attached to the optical film lid via double-sided
tape. The vent was fabricated from a filter pipette tip (10 μL)
that was also attached to the lid via double-sided tape. The
vent allowed air to be expelled when the sample chamber
was filled. The assembly and interfacing of the IFAST the de-
vice was the same for both the 3-chamber and 5-chamber
chip designs.
DNA extraction by IFAST
The sample introduction setup was prepared as follows. Prior
to attachment of the optical film lid, 1 μL silica-coated PMPs
(80 mg mL−1) suspended in storage buffer were added to the
sample chamber. The PMPs were held in place by a handheld
neodymium–iron–boron (NdFeB) magnet (12 × 3 × 3 mm3,
Magnet Sales, UK) while the buffer was removed via pipette.
Solid GuHCl, a chaotropic salt that facilitates cell lysis, pro-
tein denaturation and the binding of DNA to silica surfaces,
was then also added to the sample chamber, after which the
optical film lid and interface was sealed onto the PDMS de-
vice. With the chip prepared, 400 μL of sample (either bacte-
rial broth or liquid stool) was added to the chamber through
the septum via a pipette. Bacterial broth samples were made
up of E. coli cells cultured overnight in nutrient broth at 37
°C and 150 rpm. Stool samples were added to molecular biol-
ogy grade water to a total volume of 400 μL. For the 3-cham-
ber chip design; the final elution chamber was then filled
with purified water (10 μL), followed by the immiscible phase
being added to its chamber (10 μL). For the 5-chamber chip
design the final elution chamber was filled with purified wa-
ter (10 μL), followed by the central washing chamber being
filled with 5 M GuHCl solution (10 μL) and then the immisci-
ble phase was added to its two chambers (10 μL each).
As described earlier, a number of immiscible phases have
been used as the washing solution in IFAST, including liquid
wax,39 paraffin wax,40 olive oil,28 and air.41–44 Here, mineral
oil was chosen as the immiscible phase due to its purity and
compatibility with downstream biochemical applications.
Upon addition of the sample to the chamber, a handheld
magnet was used to mix the PMPs with the sample for 5 min,
reconstituting the GuHCl to a concentration of 5 M and
allowing binding of the DNA to the particles. Finally, the
PMPs were quickly transferred across the immiscible barrier
by the handheld magnet and into purified water, where the
DNA was allowed to elute from the particles for 2 min
(Fig. 1). Unwanted components of the stool sample matrix
were left behind in the sample chamber. The use of oil
phases in both the 3- and 5-chamber chip designs acted to re-
move potential PCR inhibitors, such as complex polysaccha-
rides, from the stool samples. In addition, the 5-chamber
chip contained an additional wash step (5 M GuHCl) to en-
sure the DNA remained bound to the PMPs and could be sep-
arated from any remaining inhibitors, as previously described
with other types of biological samples.28
Several parameters were tested using the described DNA
extraction process, including: (i) lysis efficiency of Gram-
negative bacterial cells (E. coli) using powdered GuHCl stored
in the sample chamber (‘Evaluation of stored reagents pa-
rameters’ section), (ii) DNA extraction efficiency from cul-
tured bacterial cells (E. coli) (‘DNA extraction efficiency’ sec-
tion), (iii) evaluation of purity of DNA extracted from real
clinical stool samples (‘Evaluation of clinical stool samples’
section), and (iv) amplification of H. pylori targets following
IFAST-based extraction (‘Evaluation of clinical stool samples’
section).
Analysis of extracted DNA
Following the IFAST extraction process described above, the
PMPs were held in the elution chamber via a magnet, and
the elution solution removed for analysis. DNA concentration
and purity were assessed by measuring the absorbance of 2
μL of elution solution, at 260 and 280 nm, using a
Multiskan™ GO Microplate Spectrophotometer.
DNA amplification was achieved using a 25 μL polymerase
chain reaction (PCR) mixture prepared from the following: 5
μL of purified template DNA solution (taken directly from the
IFAST device), 0.4 μM each primer, 1× Biomix™ containing
0.2 mM each dNTPs, reaction buffer (100 mM Tris-HCl [pH
8.3], 500 mM KCl, 2.5 mM MgCl2, and 0.01% (w/v) gelatin),
and 2.5 U of Taq DNA polymerase. Samples were run on a
Q-cycler 96 thermal cycler under the following conditions: an
initial denaturation at 94 °C for 10 minutes followed by 40 cy-
cles of 94 °C for 2 minutes, 55 °C for 2 minutes and 72 °C for
2 minutes, with a final extension of 72 °C for 10 minutes.
Following amplification, PCR products and a DNA size
ladder (Hyperladder V) were run on a 2% (w/v) agarose gel
until adequate separation had been achieved and visualised
using a UV transilluminator.
Results and discussion
Device operation
IFAST and its comparative technologies have proven very suc-
cessful for nucleic acid purification,28–32 but certain aspects
of the method require consideration. IFAST relies on the for-
mation of a stable interface between the aqueous and oil
phases, yet it must also allow the particles to penetrate
through the washing solution. This is not trivial and requires
careful modulation of the interfacial energy at the sample/oil/
Fig. 3 (a) Schematic of the 5-chamber DNA purification device. (b)
Photograph of the PDMS chip filled with inks and oil.
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elution interfaces. Conventional lysis and DNA binding
buffers contain detergents that would lower the interfacial
energy and can lead to the formation of an unstable inter-
face. We therefore opted for the use of 5 M GuHCl as the
binding agent. In accordance with the IFAST extraction meth-
odology described in the experimental section ‘DNA extrac-
tion by IFAST’, 400 μL of either E. coli cell suspension or liq-
uid stool sample was introduced into the sample chamber,
followed by addition of elution, wash and immiscible phases
into the relevant chambers. Addition of the biological sample
allowed resuspension of the solid GuHCl and PMPs that were
stored in the device. Manipulation of the PMPs via a hand-
held magnet enabled reconstitution of the GuHCl and
allowed binding of the DNA to the PMPs, a process that took
5 min. The particles were then transferred from the sample
chamber to the elution chamber, through the immiscible
phase(s), by moving the magnet below each of the chambers
in turn. Once in the final chamber, the DNA was allowed to
elute from the PMPs for 2 min. Transfer of the PMPs enabled
a 40-fold reduction in sample volume for analysis, from 400
μL of E. coli in nutrient broth or stool sample to 10 μL of elu-
tion buffer, in only 7 min.
Evaluation of stored reagent parameters
The use of GuHCl as the lysis and binding reagent resulted
in the following benefits: (1) the interfacial energy between
the immiscible phases was increased due to the lack of
added detergent, and (2) the increase in sample volume nor-
mally observed due to the addition of lysis and binding
buffer is significantly reduced thanks to the fact that the
GuHCl is reconstituted in the biological sample itself.49 Fur-
thermore, it has been shown that GuHCl can be used to lyse
cells and release DNA on-chip,49 and so this allows lysis of
the bacterial cells to release and bind the DNA to the PMPs
in a single step. A comparison was made between off-chip
chemical lysis and on-chip chemical lysis, using direct addi-
tion of GuHCl powder to achieve a final concentration of 5 M
in the sample solution (cultured E. coli cells as a model Gram
negative specimen). Conventional off-chip thermal lysis was
used as a control for comparison, whereby the biological
sample was placed in a heat block for 5 min at 100 °C. Lysis
was measured in terms of the total amount of DNA released
from the cells once they had undergone treatment. Efficiency
of the chemical lysis treatments is presented as a comparison
to conventional thermal lysis. No significant difference was
observed between efficiency of the on-chip and off-chip
chemical lysis protocols (p = 0.928, ANOVA) but both proto-
cols were more effective when dealing with a smaller number
of target cells (p = 0.004, ANOVA) (Fig. 4). The lysis efficiency
was also evaluated for a model Gram-positive specimen
(Staphylococcus aureus) in order to evaluate whether the pro-
posed system would be suitable for all types of bacteria. Suc-
cessful lysis of Gram-positive bacteria was also demonstrated
using the on-chip lysis method.
The amount of particles that can be used in the IFAST de-
vice was restricted by the geometry of the microfluidic con-
duits. Previous studies demonstrated that 0.24 mg of
MagneSil PMPs could be transported across the immiscible
phase without particle loss or blocking of the device, and
therefore this amount was chosen to achieve maximum DNA
binding and transport.50
DNA extraction efficiency
The DNA extraction efficiency was measured by adding
known amounts of DNA (using cultured E. coli cells as a
model Gram-negative specimen) into the sample chamber on
the 3-chamber IFAST device and comparing this to the
amount of DNA recovered from the elution chamber. DNA ex-
traction efficiency was shown to be greater when smaller
amounts of DNA were present in the system, which is ideal
for dealing with low levels of infection in clinical specimens
(Fig. 5). The amount of PMPs used per reaction had the ca-
pacity to bind 320 ng of DNA, therefore the concentrations
tested were below the saturation point of the particles.51
Negative controls were also included, in which samples
containing no DNA were added to the IFAST device and
Fig. 4 Lysis efficiency of the stored 5 M GuHCl reagent both on- and
off-chip (n = 6) for 2.54 × 106 (black) and 2.54 × 104 cells (grey).
Fig. 5 DNA extraction efficiency showing a strong linear correlation
(Pearson's R, R2 = 0.98259) between the amount of DNA added to the
system (ng) and the amount of DNA recovered from the system (ng).
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underwent the DNA extraction process. No DNA was detected
in the eluent of these samples (n = 3).
Evaluation of clinical stool samples
Known H. pylori positive stool samples from a local clinic
were analysed for DNA concentration and purity after pro-
cessing on the 3-chamber IFAST device. As expected, the DNA
concentrations obtained varied from patient to patient due to
varying levels of infection (Table 1). Some patients may have
had a severe infection, increasing the DNA concentration,
while others may have had a persisting infection after
finishing antibiotics, thereby exhibiting a low DNA concentra-
tion. However, DNA purity values were consistently poor with
a range of values between 1.1 and 1.3 (a value of between 1.8
and 2.0 indicates a ‘pure’ sample). Stool samples which had
tested negative for H. pylori using the Proflow™ H. pylori test
(ProLab, UK) were also analysed as control samples.
Following PCR, weak or no PCR products were observed,
indicating that the samples were not sufficiently pure and
free of inhibitors for successful amplification to be achieved.
Therefore the chip design was modified to include an addi-
tional wash step, yielding the 5-chamber design shown in
Fig. 3. An improvement was seen in the purity of the extracted
samples using the modified chip design, with purity values
up to 2.0 obtained (Table 2). In order to account for the wide
variety in composition of stools, all subsequent samples
analysed were assigned a value based on the Bristol Stool
Chart which classifies samples on a 7-point scale from sepa-
rate hard lumps (type 1) to entirely liquid (type 7), with an
ideal stool being smooth and sausage-like (type 4).52 Compar-
ison of the purity of the samples to their original appearance
(based on values assigned from the Bristol Stool Chart)
showed a strong correlation (R = 0.96 and P < 0.001
Pearson's R), with more liquid samples (e.g. types 6 and 7)
producing higher extracted DNA purities. However, there was
no correlation between the appearance of the stool and the
amount of DNA that was obtained. In addition, successful
amplification of the UreC target gene (PCR product size = 274
bp) was achieved on those samples which were extracted
using the IFAST device (Fig. 6). As expected, no PCR products
were observed for those stool samples which had previously
tested negative for H. pylori. None of the clinical samples
tested proved positive for CagA (expected PCR product size =
400 bp).
Conclusions
Microfluidic devices are of great potential for use in POC set-
tings as they can be fully automated, allowing for minimum
user intervention and reagent use, as well as reduced analysis
times. However, the integration of real-world interfaces for
sample introduction has often been neglected, especially with
regards to large volumes of crude samples that contain only
low concentrations of analyte. The aim of our work was there-
fore to develop a sample introduction interface which ad-
dresses these issues. The presented device bridges the gap
between microfluidics and the requirements of real sample
processing by enabling DNA purification and 40-fold pre-con-
centration within 7 min from crude stool samples.
IFAST has been previously demonstrated for rapid nucleic
acid and cell purification purposes, and here we have signifi-
cantly adapted the procedure to enable analysis of stool sam-
ples via a real-world interface. Firstly, our design includes a
large sample reservoir that accommodates 400 μL of crude
sample without the need for sample pre-treatment. For clini-
cal samples, the target analyte concentration may be very low
and therefore the larger the sample volume that can be ac-
commodated the more likely the chances of successful extrac-
tion of the target of interest. Secondly, on-chip cell lysis and
DNA binding to the solid phase supports (PMPs) was
achieved on-chip by preloading the chamber with the solid
chaotrope49 and dried PMPs. Furthermore, sample loading
was facilitated by an incorporated septum (Fig. 2b and c),
keeping the sample sealed within the chamber. In a recent
publication, cell lysis and DNA binding was performed on an
IFAST device and proven to be as efficient as off-chip cell ly-
sis prior to IFAST extraction,32 but required the addition of
lysis buffer to the sample and incubation of 30 minutes in an
oven. By comparison, the method described here requires
only the addition of the crude sample to reconstitute the
Table 1 DNA concentration and purity values from H. pylori infected
clinical stool samples using the 3-chamber IFAST chip design
Sample DNA concentration (ng μl−1) Purity (260 nm/280 nm)
1 31.8 1.3
2 63.5 1.1
3 19.1 1.3
4 295.0 1.1
5 93.8 1.2
6 154.0 1.3
Average 109.5 1.2
Table 2 DNA concentration and purity values from H. pylori infected
clinical stool samples using the 5-chamber IFAST chip design.
Sample Appearancea DNA concentration (ng μl−1) 260/280
1 2 5.1 1.2
2 1 22.8 1.0
3 5 43.4 1.7
4 6 20.0 1.8
5 1 54.1 1.3
6 4 84.4 1.7
7 7 54.7 2.0
8 1 190.0 1.2
Average 59.3 1.5
a Score based on comparison to Bristol Stool Chart.
Fig. 6 Gel electrophoresis image showing: (L) DNA size ladder; (1–8)
amplified faecal samples extracted using the IFAST device; (N) negative
control.
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solid GuHCl and PMPs. This allows easy storage on the
microfluidic device; increasing analysis speed and user
friendliness. Detergent-free lysis is not a requirement for
IFAST-based analysis as such systems have been shown to be
compatible with common lysis and elution buffers containing
detergents such as 1% Triton X-100, 1% LiDS or 2% SDS.28
The ability to reconstitute the reagent to a known concentra-
tion in the sample itself also makes it easier for the operator
to use and reduces the number of manual steps required.
Thirdly, instead of bonding the PDMS microfluidic layer to a
glass substrate, we opted for an optical adhesive film as the
bottom substrate of the chip. This very simple and rapid
bonding approach has the added benefit that its hydrophobic
surface properties allow the transfer of magnetic particles
through the immiscible barrier without the addition of deter-
gents to lower the interfacial energy. It also has advantages
over plasma bonding in terms of ease of use and accessibility
to equipment. Not every lab has access to a plasma oven for
bonding but the optical adhesive is readily available from a
number of suppliers and is more cost effective and easier to
use. It is also specifically designed for PCR-based applica-
tions and has good optical properties which would be benefi-
cial for future integration of real-time isothermal amplifica-
tion to create a complete point-of-care system.
This miniaturised approach offers advantages over current
commercially available stool DNA extraction kits, such as the
QIAamp Stool DNA Mini Kit, as it offers a 7 fold reduction in
the time taken for analysis, enables further pre-concentration
of target DNA by eluting in a volume of 10 μL compared to
200 μL and is easy to use (e.g. multiple heating and centrifu-
gation steps are not required, no proprietary chemicals are
used).53
The simplicity and ease of use of the presented real world
interface is perfectly suited for the requirements of a POC di-
agnostic device as results can be obtained whilst the patient
is waiting, ensuring rapid identification of pathogenic strains
of H. pylori from stool samples. Future work would look at
evaluating the IFAST system with additional stool samples,
allowing replicates of all possible sample types (based on the
Bristol Stool Chart) to be performed, particularly with respect
to the purity of the eluted DNA. This would also allow a more
in depth study to be carried out on the number of H. pylori
positive samples which express CagA. In addition, future
work aims to integrate this work with real-time isothermal
amplification of the pathogenic target to create a complete
point-of-care system. This could lead to more immediate
therapy and potentially a reduction in adverse conditions as
a result of infection, such as gastric carcinogenesis. The
microfluidic system could also be readily adapted to accom-
modate other pathogenic targets present in stool samples,
such as Clostridium difficile or rotavirus.
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